Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**SFT 4002** is an investigational inhaled respiratory drug-device combination program developed by invoX Pharma for **asthma** and **chronic obstructive pulmonary disease**. invoX lists the candidate in its Softhaler® respiratory pipeline at Phase 2. The active pharmaceutical ingredient, molecular modality, pharmacologic target, and mechanism of action have not been publicly disclosed. Softhaler® is a propellant-free soft-mist inhalation platform that mechanically converts a liquid formulation into an ultra-fine aerosol for pulmonary delivery; it is not a dry-powder inhaler.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SFT 4002.